Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of COVID‐19
Sarah Blach(Center for Disease Analysis), Soo Aleman(Karolinska University Hospital), Devin Razavi‐Shearer(University of Health Sciences Antigua), Martin Kåberg(Karolinska University Hospital), Homie Razavi(Center for Disease Analysis), Per‐Erik Klasa(Public Risk Management Association), Anna Jerkeman(Lund University), Marianne Alanko Blomé(Lund University), Ann‐Sofi Duberg(Örebro University), Martin Lagging(Sahlgrenska University Hospital)
Cited by 19
Related Papers
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030
|Journal of Hepatology|2018|2k
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
|The Lancet. Gastroenterology & hepatology|2019|539
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm
|Journal of Viral Hepatitis|2014|484
Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study
|The Lancet. Gastroenterology & hepatology|2023|399